Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M7,852Revenue (TTM) $M40.8Net Margin (%)-798.7Altman Z-Score23.8
Enterprise Value $M7,383EPS (TTM) $-7.4Operating Margin %-761.1Piotroski F-Score4
P/E(ttm)--Beneish M-Score415Pre-tax Margin (%)-798.7Higher ROA y-yN
Price/Book15.210-y EBITDA Growth Rate %--Quick Ratio11.4Cash flow > EarningsY
Price/Sales1675-y EBITDA Growth Rate %--Current Ratio11.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-83.2Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-152.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M53.4ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with TSRO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
TSROJoel Greenblatt 2016-09-30 Buy $81.06 - $108.59
$ 147.0057%New holding2,535
TSRORon Baron 2016-09-30 Reduce$81.06 - $108.59
$ 147.0057%Reduce -32.43%2,500
TSRORon Baron 2016-06-30 Add$37.21 - $84.05
$ 147.00230%Add 85.00%3,700
TSRORon Baron 2016-03-31 Buy $32.01 - $52.32
$ 147.00266%New holding2,000
TSRODavid Swensen 2015-12-31 Sold Out -0.08%$40.35 - $52.91
$ 147.00206%Sold Out0
TSRODavid Swensen 2015-09-30 Buy 0.08%$38.97 - $65.8
$ 147.00169%New holding6,238
TSROLeon Cooperman 2015-06-30 Sold Out -0.05%$50.84 - $64.65
$ 147.00156%Sold Out0
TSROLeon Cooperman 2015-03-31 Buy 0.05%$36.62 - $61.41
$ 147.00212%New holding50,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TSRO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

TSRO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Huber Martin H. Jr.SVP & Chief Medical Officer 2017-01-03Sell190$136.267.88view
English Edward CVP of Finance and Admin. 2016-12-12Sell10,000$129.0513.91view
Huber Martin H. Jr.SVP & Chief Medical Officer 2016-11-02Sell327$121.2921.2view
Huber Martin H. Jr.SVP & Chief Medical Officer 2016-09-22Sell408$108.1235.96view
English Edward CV.P.Finance and Administration 2016-09-08Sell7,000$88.5466.03view
Hanke Jeffrey H.Executive VP, R&D and CSO 2016-08-30Sell29,166$86.0470.85view
Hanke Jeffrey H.Executive VP, R&D and CSO 2016-06-30Sell12,500$74.3597.71view
English Edward CVP of Finance & Administration 2016-06-10Sell7,000$40.75260.74view
Weller Harry R10% Owner 2016-03-18Buy1,420,858$35.19317.73view
Viswanathan Ravi10% Owner 2016-03-18Buy1,420,858$35.19317.73view

Quarterly/Annual Reports about TSRO:

News about TSRO:

Articles On GuruFocus.com
7 Stocks Outperforming the Market Jan 12 2017 
Steven Cohen's Assets With Highest Returns Dec 30 2016 
A Tesaro Catalyst the Markets Seem to Have Overlooked Dec 20 2016 
Pioneer Investments Continues to Buy Alibaba, 8 Others Dec 07 2016 
Major Second Quarter Purchases for Cohen include Tesaro, Pernix Jul 20 2016 
Steven Cohen Hits Another Home Run in Oncology Jul 07 2016 
David Swensen Bets on Antero Resources Mar 10 2016 
David Swensen's Transactions Show Diversity of Portfolio Nov 19 2015 

More From Other Websites
Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017 Jan 20 2017
Tesaro Announces Opening of Niraparib Expanded Access Program for U.S. Patients With Ovarian Cancer Jan 17 2017
Trump's 'Disastrous' Pharma View Doesn't Rattle JPMorgan Drug Conference Jan 13 2017
The Three Most Important Questions For TESARO Inc (TSRO) Shareholders Right Now Jan 13 2017
TESARO Varubi IV Gets Complete Response Letter in the U.S. Jan 13 2017
Coverage initiated on Tesaro by Morgan Stanley Jan 13 2017
Tesaro Stock Rebounds Despite FDA Holdup On Anti-Nausea Med Jan 12 2017
TESARO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 12 2017
Latest drug by Waltham drugmaker Tesaro rejected by FDA Jan 12 2017
TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA Jan 11 2017
4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal Jan 10 2017
TESARO, INC. Files SEC form 8-K, Results of Operations and Financial Condition Jan 09 2017
6 Major FDA Decisions and Biopharma Catalysts Coming in January and February Jan 06 2017
What We’re Watching In Biotech For January: Otonomy Inc (OTIC) And TESARO Inc (TSRO) Jan 03 2017
Which Top 5 Biotech Stocks In 2016 Are Slated For Triple-Digit Gains? Dec 30 2016
Which Top 5 Biotech Stocks In 2016 Are Slated For Triple-Digit Gains? Dec 30 2016
7 Key FDA Decisions and Catalysts Expected in January and February Dec 30 2016
Let’s call this the no-fault stock market Dec 29 2016
Take-Two A Top Pick, Tesaro A Buy, Ritchie Bros. Downgraded Dec 27 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)